Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Attacking Acquired Mutations: Researchers Aim to Make Molecularly Targeted Cancer Therapies "Smarter"

August 8th 2014

Hailed as "new ammunition in the war against cancer" and featured in TIME magazine at the turn of the new millennium, molecularly targeted therapies have gone on to revolutionize cancer treatment. Clinical responses, however, are all too often short-lived as cancer cells become resistant.

PALB2, BRCA2 Gene Mutations Confer Similar Breast Cancer Risk

August 7th 2014

Women harboring a loss-of-function mutation in the PALB2 gene demonstrated an increased risk of developing breast cancer that was similar to the predisposition seen with mutations in the infamous BRCA gene

Maintaining a Framework In Molecular Diagnostic Testing

August 6th 2014

Nobody disputes the need for careful, judicious diagnostic testing. But as the number of individual gene tests continues to grow, clinicians are struggling to keep up. On the one hand, using diagnostic markers like KRAS in colon cancer or hormone receptor status in breast cancer to select the most appropriate chemotherapy regimen is essential.

Evolving Therapeutic Landscape in Breast Cancer

August 5th 2014

Case Studies: Treating Metastatic Breast Cancer

August 5th 2014

Clinical Setting for Eribulin in Metastatic Breast Cancer

August 5th 2014

Treatment Strategies in ER-Positive Breast Cancer

August 5th 2014

First-Line ER-Positive MBC Treatments

August 5th 2014

Changing Treatment Landscape in Metastatic Breast Cancer

August 5th 2014

Novel EGFR Specific Agents Impress in NSCLC

August 2nd 2014

Third generation EGFR TKIs have demonstrated dramatic benefits for patients with non-small cell lung cancer (NSCLC) and should be considered as a standard second-line option following resistance to frontline therapy

Dr. Hirsch Discusses the Role of Next-Generation EGFR Inhibitors

August 1st 2014

Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the role of next-generation EGFR inhibitors.

Glycans Emerge as Promising Biomarkers for Early Detection of Many Cancer Types

July 30th 2014

For many years, we in the medical and research communities have tried to use proteins and DNA fragments as disease markers to find cancer early.

Promising Findings for Afatinib-Cetuximab Combo in Previously Treated EGFR-Mutant Lung Cancer

July 29th 2014

Results of an early-phase study have shown the combination of afatinib (Gilotrif) and cetuximab (Erbitux) has utility in EGFR-mutant lung cancer patients who have developed resistance to gefitinib (Tarceva) and erlotinib (Iressa).

Final Thoughts on Optimizing the Treatment of mCRC

July 23rd 2014

TAS-102 in Refractory mCRC

July 23rd 2014

Optimizing Treatment With Regorafenib in mCRC

July 23rd 2014

BRAF-Mutated Colorectal Cancer

July 23rd 2014

Second-Line Treatment Options in mCRC

July 23rd 2014

Future Analyses From the 80405 mCRC Trial

July 23rd 2014

Conducting Extended RAS Testing in CRC

July 23rd 2014